强生10亿美元收购BeneVir Biopharm公司推进溶瘤免疫疗法

2018-05-03 MedSci MedSci原创

强生旗下的杨森Janssen签署了一份最终协议,将收购一家私人控股的生物制药公司--BeneVir Biopharm,该公司一直致力于溶瘤病毒作用的免疫疗法。

强生旗下的杨森Janssen签署了一份最终协议,将收购一家私人控股的生物制药公司--BeneVir Biopharm,该公司一直致力于溶瘤病毒作用的免疫疗法。

BeneVir公司利用其专有的T-Stealth溶瘤病毒平台来设计能够感染和破坏癌细胞的溶瘤病毒。溶瘤病毒可以诱导T细胞向肿瘤部位的浸润,增强免疫检查点抑制剂的疗效。但是其在临床应用中的最大障碍是免疫检查点抑制剂在增强T细胞免疫的同时,也加速了自身免疫系统对外源病毒(有益的溶瘤病毒)的清除。而BeneVir公司的T-Stealth溶瘤病毒可以逃逸免疫系统的攻击,让溶瘤病毒与免疫检查点抑制剂的联用可能实现。

杨森研发部全球肿瘤治疗领域主管Peter Lebowitz表示:"溶瘤病毒免疫治疗能够激发和增强肿瘤免疫应答,在实体瘤的治疗中具有非常大的潜力。BeneVir公司独特的技术平台补充我们的肿瘤免疫方面的研究,我们将开展一系列新的免疫疗法组合研究,以改善患者的治疗效果。"

杨森表示将推动T-Stealth溶瘤病毒作为单独疗法,以及与其他免疫疗法联合用于治疗多种实体瘤(例如肺癌、前列腺癌、结肠癌等)。

原始出处:


此文系梅斯医学(MedSci)原创整理编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787466, encodeId=8e1b1e87466d0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Mar 27 22:46:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943687, encodeId=29e2194368e27, content=<a href='/topic/show?id=89713341a9' target=_blank style='color:#2F92EE;'>#BeneVir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3341, encryptionId=89713341a9, topicName=BeneVir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Jan 09 13:46:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707542, encodeId=22351e0754224, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Thu Jul 19 23:46:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918060, encodeId=c8b119180600b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 09 03:46:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271676, encodeId=c7dc12e167663, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat May 05 10:46:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311735, encodeId=dd7e311e3550, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu May 03 22:52:10 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311722, encodeId=405c311e228c, content=强生旗下的杨森Janssen签署了一份最终协议.将收购一**人**的生物制药公司--BeneVirBiopharm.该公司一直致力于溶瘤病毒作用的免疫疗法., beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Thu May 03 22:28:03 CST 2018, time=2018-05-03, status=1, ipAttribution=)]
    2019-03-27 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787466, encodeId=8e1b1e87466d0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Mar 27 22:46:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943687, encodeId=29e2194368e27, content=<a href='/topic/show?id=89713341a9' target=_blank style='color:#2F92EE;'>#BeneVir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3341, encryptionId=89713341a9, topicName=BeneVir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Jan 09 13:46:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707542, encodeId=22351e0754224, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Thu Jul 19 23:46:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918060, encodeId=c8b119180600b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 09 03:46:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271676, encodeId=c7dc12e167663, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat May 05 10:46:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311735, encodeId=dd7e311e3550, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu May 03 22:52:10 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311722, encodeId=405c311e228c, content=强生旗下的杨森Janssen签署了一份最终协议.将收购一**人**的生物制药公司--BeneVirBiopharm.该公司一直致力于溶瘤病毒作用的免疫疗法., beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Thu May 03 22:28:03 CST 2018, time=2018-05-03, status=1, ipAttribution=)]
    2019-01-09 许安
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787466, encodeId=8e1b1e87466d0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Mar 27 22:46:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943687, encodeId=29e2194368e27, content=<a href='/topic/show?id=89713341a9' target=_blank style='color:#2F92EE;'>#BeneVir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3341, encryptionId=89713341a9, topicName=BeneVir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Jan 09 13:46:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707542, encodeId=22351e0754224, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Thu Jul 19 23:46:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918060, encodeId=c8b119180600b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 09 03:46:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271676, encodeId=c7dc12e167663, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat May 05 10:46:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311735, encodeId=dd7e311e3550, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu May 03 22:52:10 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311722, encodeId=405c311e228c, content=强生旗下的杨森Janssen签署了一份最终协议.将收购一**人**的生物制药公司--BeneVirBiopharm.该公司一直致力于溶瘤病毒作用的免疫疗法., beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Thu May 03 22:28:03 CST 2018, time=2018-05-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787466, encodeId=8e1b1e87466d0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Mar 27 22:46:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943687, encodeId=29e2194368e27, content=<a href='/topic/show?id=89713341a9' target=_blank style='color:#2F92EE;'>#BeneVir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3341, encryptionId=89713341a9, topicName=BeneVir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Jan 09 13:46:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707542, encodeId=22351e0754224, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Thu Jul 19 23:46:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918060, encodeId=c8b119180600b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 09 03:46:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271676, encodeId=c7dc12e167663, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat May 05 10:46:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311735, encodeId=dd7e311e3550, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu May 03 22:52:10 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311722, encodeId=405c311e228c, content=强生旗下的杨森Janssen签署了一份最终协议.将收购一**人**的生物制药公司--BeneVirBiopharm.该公司一直致力于溶瘤病毒作用的免疫疗法., beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Thu May 03 22:28:03 CST 2018, time=2018-05-03, status=1, ipAttribution=)]
    2018-06-09 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787466, encodeId=8e1b1e87466d0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Mar 27 22:46:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943687, encodeId=29e2194368e27, content=<a href='/topic/show?id=89713341a9' target=_blank style='color:#2F92EE;'>#BeneVir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3341, encryptionId=89713341a9, topicName=BeneVir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Jan 09 13:46:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707542, encodeId=22351e0754224, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Thu Jul 19 23:46:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918060, encodeId=c8b119180600b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 09 03:46:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271676, encodeId=c7dc12e167663, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat May 05 10:46:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311735, encodeId=dd7e311e3550, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu May 03 22:52:10 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311722, encodeId=405c311e228c, content=强生旗下的杨森Janssen签署了一份最终协议.将收购一**人**的生物制药公司--BeneVirBiopharm.该公司一直致力于溶瘤病毒作用的免疫疗法., beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Thu May 03 22:28:03 CST 2018, time=2018-05-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1787466, encodeId=8e1b1e87466d0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Mar 27 22:46:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943687, encodeId=29e2194368e27, content=<a href='/topic/show?id=89713341a9' target=_blank style='color:#2F92EE;'>#BeneVir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3341, encryptionId=89713341a9, topicName=BeneVir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Jan 09 13:46:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707542, encodeId=22351e0754224, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Thu Jul 19 23:46:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918060, encodeId=c8b119180600b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 09 03:46:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271676, encodeId=c7dc12e167663, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat May 05 10:46:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311735, encodeId=dd7e311e3550, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu May 03 22:52:10 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311722, encodeId=405c311e228c, content=强生旗下的杨森Janssen签署了一份最终协议.将收购一**人**的生物制药公司--BeneVirBiopharm.该公司一直致力于溶瘤病毒作用的免疫疗法., beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Thu May 03 22:28:03 CST 2018, time=2018-05-03, status=1, ipAttribution=)]
    2018-05-03 1e1b8538m79(暂无匿称)

    不错的文章值得拥有

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1787466, encodeId=8e1b1e87466d0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Mar 27 22:46:00 CST 2019, time=2019-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943687, encodeId=29e2194368e27, content=<a href='/topic/show?id=89713341a9' target=_blank style='color:#2F92EE;'>#BeneVir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3341, encryptionId=89713341a9, topicName=BeneVir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Wed Jan 09 13:46:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707542, encodeId=22351e0754224, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Thu Jul 19 23:46:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918060, encodeId=c8b119180600b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 09 03:46:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271676, encodeId=c7dc12e167663, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat May 05 10:46:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311735, encodeId=dd7e311e3550, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu May 03 22:52:10 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311722, encodeId=405c311e228c, content=强生旗下的杨森Janssen签署了一份最终协议.将收购一**人**的生物制药公司--BeneVirBiopharm.该公司一直致力于溶瘤病毒作用的免疫疗法., beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Thu May 03 22:28:03 CST 2018, time=2018-05-03, status=1, ipAttribution=)]
    2018-05-03 有备才能无患

    强生旗下的杨森Janssen签署了一份最终协议.将收购一**人**的生物制药公司--BeneVirBiopharm.该公司一直致力于溶瘤病毒作用的免疫疗法.

    0

相关资讯

Immunity:除了溶瘤病毒,这种药物竟也能让免疫疗法更有效

免疫疗法的成功使癌症治疗进入了新的时代。近几年,美国FDA已批准多种癌症免疫疗法上市,包括免疫检查点抑制剂(如CTLA-4抗体、PD-1/PD-L1抗体)、双特异性抗体、溶瘤病毒、CAR-T疗法等。

Cell:效果喜人!多国科学家首次证明,溶瘤病毒联合PD-1抑制剂免疫治疗可以大幅提升癌症响应率

研究人员先是向黑色素瘤局部注射溶瘤病毒,破坏肿瘤微环境,然后全身系统性静脉应用PD-1抑制剂,激活和增强T细胞对肿瘤细胞的攻击和杀伤。这就好比围剿敌方老巢时,先发射导弹进行战略轰炸,再派特种部队全面清剿。

Sci Transl Med:癌症治愈新希望,溶瘤病毒结合免疫疗法癌症治愈率可达90%

近些年来,免疫治疗的发展为癌症的治疗带来了一线曙光。免疫治疗指的是使身体的免疫系统攻击癌症,对诸如黑色素瘤和白血病等癌症带来了革命性的突破。然而,许多其它类型的癌症仍然具有抗性。

Sci Transl Med:溶瘤病毒与药物携手消灭肿瘤

溶瘤病毒是一种有效的治疗癌症手段,但是它们需要感染肿瘤细胞才能发挥作用。肿瘤对溶瘤病毒疗法产生抗性的原因通常是肿瘤细胞不再能够被溶瘤病毒感染。

Science:两项重磅研究同日上线,溶瘤病毒联合免疫疗法挑战致命乳腺癌和脑胶质瘤,火力全开

今日,顶级学术期刊《Science Translational Medicine》以封面故事的形式,同时上线了肿瘤免疫疗法领域两项重磅研究成果,并且都是关于免疫检查点抑制剂联合溶瘤病毒治疗侵袭性实体瘤的突破性进展。Cover Story(图片来源Science Translational Medicine)近年来,虽然以免疫检查点抑制剂(PD-1/L1)为代表的免疫疗法)对于癌症治疗已经显示出

J CLIN ONCOL :溶瘤病毒对抗脑瘤!临床1期显示:显著延长患者生存期

“一种常见的感冒病毒经过‘改造’后,能够攻击致命的脑瘤,延长患者的生存期”——这是一项发表在《Journal of Clinical Oncology》期刊上的最新成果。来自于德克萨斯大学MD安德森癌症中心的研究人员刚刚完成了临床Ⅰ期试验,并获得喜人的成绩。